Novartis announced top line results of its ianalumab (VAY736;B cell inhibitor) in primary Sjögren’s dz. 2 RCTs, NEPTUNUS-1 and NEPTUNUS-2, met met primary endpoints w/ statistically significant improvements in disease activity in Sjögren’s patients. https://t.co/cIBhF3YJh3 https://t.co/RpZGe0Sa0K
Links:
Novartis announces both ianalumab Phase III clinical trials met primary endpoin…
https://buff.ly/c6COFPw
Dec-31-2025
